Dr. Donald Poirier has been a professor at the Department of Molecular Medicine (Faculty of Medicine, Laval University, Québec, Qc) since July 1991 as well as a researcher at the CHU de Québec – Research Center (Québec, Qc). Since 2008, he has also been Director of the Organic Synthesis Service and Co-Director of the Analytical and Medicinal Chemistry Platform.

Professor Poirier received his basic training in organic chemistry (PhD from Laval University, 1980-1985) and subsequently specialized in medicinal chemistry and endocrinology (Postdoctoral studies at the CHUL-Research Center, 1986-1990, CRM fellowship) and more recently in solid phase synthesis of small molecules of therapeutic interest such as steroid derivatives. He is especially interested in the development of steroidogenic enzyme (17b-HSDs, steroid sulfatase, CYP1B1) inhibitors and antitumor agents for the treatment of different cancers (breast, prostate, ovary, pancreatic, and leukemia). As examples, he developed the first non-estrogenic irreversible steroidal inhibitor of 17β-HSD1 for the treatment of breast cancer and endometriosis. He also developed a family of aminosteroid derivatives that inhibited tumor growth in mice for different cancers (breast, ovary, pancreatic, and leukemia).

In addition to the synthesis of small molecules by classical chemistry, he succeeded by developing solid-phase syntheses of C18-steroid (estrane) derivatives as well as C19-steroid (androstane) derivatives that enabled the generation of model libraries of targeted therapeutic compounds. Thus, he developed a diethylsilylacetylenic linker that produces more stable compounds and a sulfamate linker that produces two classes (phenol and sulfamate) of relevant steroidal or nonsteroidal compounds according to cleavage conditions. He is also interested in additional aspects of organic chemistry (synthesis, new methodologies, NMR analysis, etc.) and medicinal chemistry (SAR, molecular modeling, biological assays, etc.). A particularity of his research group is that he is interested in several stages of the development of a new drug: conception, chemical synthesis, in vitro biological tests (enzymatic assays, cell proliferation, etc.) and in vivo (estrogenic activities and androgenic in female and male mice, plasma concentration, metabolic stability, xenografts of cancer cells, etc.).

Professor Poirier has published 220 scientific publications and is the holder of 11 patents and patent applications. He has also been involved in more than 450 oral and poster presentations, as well as conferences as invited speaker.

CHUL
2705, boulevard Laurier
T4-50
Québec, Québec
Canada G1V 4G2
242 entries « 1 of 25 »

Poirier D, Roy J, Maltais R, Weidmann C, Audet-Walsh É

An Aminosteroid Derivative Shows Higher In Vitro and In Vivo Potencies than Gold Standard Drugs in Androgen-Dependent Prostate Cancer Models

Journal Article

Cancers (Basel), 15 (11), 2023.

Abstract | Links:

Burguin A, Roy J, Ouellette G, Maltais R, Bherer J, Diorio C, Poirier D, Durocher F

Aminosteroid RM-581 Decreases Cell Proliferation of All Breast Cancer Molecular Subtypes, Alone and in Combination with Breast Cancer Treatments

Journal Article

J Clin Med, 12 (13), 2023.

Abstract | Links:

Fouad Mansour M, Blanchette S, Pelletier M, Poirier D, Tchernof A

17β-hydroxysteroid dehydrogenase type 2 activity, expression and cellular localization in abdominal adipose tissues from women

Journal Article

Clin Endocrinol (Oxf), 98 (2), 2023.

Abstract | Links:

Ngueta AD, Roy J, Maltais R, Poirier D

Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone

Journal Article

Molecules, 28 (2), 2023.

Abstract | Links:

Maltais R, Sancéau JY, Poirier D, Marette A

A Concise, Gram-Scale Total Synthesis of Protectin DX and Related Labeled Versions via a Key Stereoselective Reduction of Enediyne

Journal Article

J Org Chem, 88 (11), 2023.

Abstract | Links:

Poirier D

Description of Chemical Synthesis, Nuclear Magnetic Resonance Characterization and Biological Activity of Estrane-Based Inhibitors/Activators of Steroidogenesis

Journal Article

Molecules, 28 (8), 2023.

Abstract | Links:

Sancéau JY, Bélanger P, Maltais R, Poirier D

An Improved Synthesis of Glucuronide Metabolites of Hindered Phenolic Xenoestrogens

Journal Article

Curr Org Synth, 19 (7), 2022.

Abstract | Links:

Poirier D, Nyachieo A, Romano A, Roy J, Maltais R, Chai D, Delvoux B, Tomassetti C, Vanhie A

An irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 inhibits estradiol synthesis in human endometriosis lesions and induces regression of the non-human primate endometriosis

Journal Article

J Steroid Biochem Mol Biol, 222 , 2022.

Abstract | Links:

Poirier D, Maltais R, Rousseau JA, Roy J, Phoenix S, Cortés-Benítez F, Lecomte R

Chemical synthesis of fluorinated and iodinated 17β-HSD3 inhibitors and evaluation for imaging prostate cancer tumors and tissue biodistribution

Journal Article

Bioorg Chem, 129 , 2022.

Abstract | Links:

Djiemeny Ngueta A, Roy J, Poirier D

Chemical synthesis, NMR characterization, and anticancer activity of androstene derivatives with a C17-side chain

Journal Article

Steroids, 186 , 2022.

Abstract | Links:

242 entries « 1 of 25 »
Signaler des ajouts ou des modifications

Active projects

  • 3alpha-hydroxysteroid dehydrogenase type 3 as a modulator of human adipose tissue function and distribution, from 2020-04-01 to 2024-03-31
  • Aminosteroid derivatives as a new class of cholesterol homeostasis disruptors for selective treatment of pancreatic cancer: Mechanistic and translational studies, from 2022-10-01 to 2027-09-30
  • Investigating TBC1D9 clinical relevance in combination with chemotherapeutic drugs in triple negative breast cancer, from 2023-06-21 to 2024-03-31

Recently finished projects

  • Évaluation du potentiel thérapeutique de la protectine DX et d'analogues contre la COVID-19 , from 2020-06-01 to 2022-03-31
  • La conception de nouveaux agents thérapeutiques et la résonance magnétique nucléaire, from 2022-01-01 to 2023-05-31
  • TBC1D9: therapeutic target of the aggressiveness of triple negative breast cancer, from 2023-03-01 to 2024-02-29
  • Un aminostéroïde actif oralement pour traiter les cancers du sein triple négatif, from 2021-09-08 to 2022-03-31
Data provided by the Université Laval research projects registery